CMSC

There can be specific times when patients with multiple sclerosis can experience a spike in their stress level. At times like these alternative medicine options like guided imagery can help reduce their stress as the progress through treatment.

Previous studies have suggested that patients with multiple sclerosis may not be able to handle a high intensity weight training program. One recent work has shown that may not be the case.

Work has been done to look at what potential benefit robotics could have on patient care for people with multiple sclerosis. While the research looks promising, bringing the technology to the people is still far on the horizon.

Treating multiple sclerosis requires the work of a number of people. One of the key members of that team is the nurse. Specially trained nurses can help ease the burden of doctors while also providing needed help to patients.

On the long list of concerns patients with multiple sclerosis have to deal with on a daily basis their sexual health may not be high on the list of priorities. By having a conversation it can be an obstacle that can be overcome.

Up to 90 percent of patients with multiple sclerosis have spinal cord pathology.

Experimental stem cell therapy using a patient's own stem cells could offer long-term relief for many patients with multiple sclerosis, though questions still remain regarding cost, patient selection, and efficacy.

When many people think of ballroom dancing they likely think of Fred Astaire and Ginger Rogers. The same steps that made them famous on the big screen could help people stay on their feet despite the challenges of multiple sclerosis.

One of the biggest concerns about patients with multiple sclerosis is their potential to have movement limited by the condition. Researchers are looking for ways to stop that from happening.

Studies of multiple sclerosis have shown that men are more severely affected by the condition and that relapse recovery can also be worse in men. While there continues to be research on the topic it is believed that testosterone can play a role.

Treating a condition like multiple sclerosis presents a number of problems for patients and healthcare professionals alike. Those challenges can change and develop over a patient's lifetime as well.

Research on spinal cord gray matter atrophy in terms of progressive multiple sclerosis has found the highest correlations between disability and gray matter volume loss within the spinal cord.

More may be known about the relapsing form of multiple sclerosis but researchers are working to learn about the progressive form of the disease as well. That includes looking for potential tools to stop neurological degeneration from harming patients.

The symptoms of neuromyelitis optica and multiple sclerosis may appear similar at first glance but an improper diagnosis can create more issues for patients than they originally experienced.

Patients with multiple sclerosis face a variety of challenges in their daily lives, especially when they experience a relapse. How they and their healthcare professionals approach these relapses can impact their overall quality of life even after the relapse passes.

Multiple sclerosis is a condition that affects a person's life over the course of many years. For those with the relapsing form that can include managing symptoms and potential relapses that come during treatment.

Medical marijuana has shown some benefits in the treatment of other health conditions, but its efficacy for patients with multiple sclerosis is still to be determined.

The issue of marijuana use is complicated for many reasons. One of the biggest, according to a recent survey is the willingness of patients and healthcare providers alike to even discuss the topic.

Alemtuzumab has been shown in clinical trials to be more effective than treatment with interferon beta-1a for patients with relapsing-remitting multiple sclerosis. However, the drug's side effect profile requires careful treatment monitoring and follow up.

Study results indicate that treatment with alemtuzumab reduces focal inflammation, with durable effects that may be due to the distinct pattern of lymphocyte depletion and repopulation after treatment.

One of the most important things for many patients with multiple sclerosis is their ability to be able to move on their own despite the condition. Sometimes the reasons they are unable to move the way they want may go beyond the original diagnosis.

In a longterm condition like multiple sclerosis finding the proper treatment option can often be a difficult task. A medication was recently approved to help patients who have struggled to find that help in the past.

Proper nutrition can benefit everyone but keeping a healthy diet can be especially important for patients with multiple sclerosis.

While it is a rare condition and no medications have been approved for its treatment patients with neuromyelitis optica can get the help they need if doctors know what they are looking for.

As more is learned about the gut microbiome researchers are finding new ways to apply it to other fields of medicine. A recent study looked at how it can affect multiple sclerosis and what role it can have in future treatment options.

Increased awareness of risk factors and symptoms among primary care physicians, prompt referral of suspected cases to specialists, and a growing armamentarium of disease-modifying drugs lead to better prognosis for patients.

A presentation at the 2015 CMSC annual meeting made the case that focal, specific, subacute, neurologic problems in otherwise healthy adults should be diligently followed, and MRI can be an useful tool in differential diagnosis.

Recent studies have revealed clues to the role played by the gut microbiome in a variety of diseases and conditions. Now researchers are looking at whether aberrant immune responses triggered by disruptions in the gut microbiome are to blame for multiple sclerosis.

Experts examine conflicting evidence regarding the continuation of disease-modifying therapy in patients with secondary progressive multiple sclerosis.

Session at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers debates whether the side effects associated with alemtuzumab, a novel anti-CD52 monoclonal antibody, might ultimately prevent its approval for the treatment of multiple sclerosis, despite evidence of clinical effectiveness.